ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021


-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation-

- Phase 2b/3 adaptive dose-ranging study planned to initiate in Q4:21-

GENEVA, Switzerland and BOSTON, MA – June 10, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant for the treatment of spontaneous preterm labor at the Royal College of Obstetricians and Gynecologists (RCOG) Virtual World Congress 2021. As previously disclosed, the PROLONG data demonstrated that ebopiprant was well tolerated and showed early evidence of efficacy in pregnant women with spontaneous preterm labor and supports the advancement into a Phase 2b/3 adaptive study.

“We are encouraged by the positive data generated to date, highlighting the unique mechanism of action and the potential clinical benefit of ebopiprant for the treatment of preterm labor to reduce the incidence of preterm birth,” said Ben Mol, Ph.D., M.D., Professor of Obstetrics and Gynaecology, Monash Medical Centre, Melbourne Australia and a leading Key Opinion Leader in preterm labor therapeutics. “A key objective in the treatment of preterm labor is to delay delivery for at least 48 hours, as this allows for the transfer of women to centers with neonatal intensive care facilities and for the peak effect of corticosteroids given to accelerate fetal lung maturation. Building on the effects seen at 48 hours and in earlier gestations at 7 days, the next clinical study will explore a range of doses to fully define and optimize the full therapeutic potential of ebopiprant. We look forward to leveraging important learnings from PROLONG in this next phase of development.”

“These positive data play a critical role in our development plans for ebopiprant, and we are excited to build on this momentum,” said Brian O’Callaghan, CEO of ObsEva. “Preparations are ongoing to initiate a Phase 2b/3 clinical study in Q4:21. We believe this adaptive study has the potential to support an accelerated registration program in Europe, and we look forward to providing additional updates on our progress later this year. We also plan to engage the FDA in discussions regarding the US clinical program for ebopiprant. With no other known compounds under development for the treatment of preterm labor, ebopiprant has the potential to be an important advancement in the prevention of preterm birth.”

The abstract, titled “A Randomised, Placebo-Controlled, Proof-of-Concept Trial of Ebopiprant for Spontaneous Preterm Labor (PROLONG),” will be presented today during an oral session by Dr. Ben Mol (Abstract #601).

Summary of the data:

  • Ebopiprant, when administered with atosiban infusion to women with preterm labor, reduced delivery in singleton pregnancies at 48 hours after the start of dosing by over 50% compared to atosiban alone.
  • Overall, 7/56 (12.5%) of women receiving ebopiprant on top of atosiban delivered within 48 hours of starting treatment compared to 12/55 (21.8%) receiving atosiban plus placebo (OR 90% CI: 0.52 (0.22, 1.23)).
  • In singleton pregnancies, 5/40 (12.5%) of women receiving ebopiprant plus atosiban delivered within 48 hours compared to 11/41 (26.8%) receiving atosiban plus placebo (OR 90% CI: 0.39 (0.15, 1.04)).
  • This difference was observed for singletons (12.5% vs 26.8%) but not for twins (12.5% vs 7.1 %).
  • The treatment effect for the overall population was more modest at 7 days, however in younger gestational ages, the percentage of women who delivered within 7 days was lower in women receiving ebopiprant on top of atosiban (23.8%) compared to women who received placebo plus atosiban (14.3%) (OR 90% CI: 0.53 (0.14, 2.01)).
  • The incidence of maternal, fetal and neonatal adverse events was comparable between the treatment groups.

The presentation is available through the RCOG conference portal, and the link to the session is also available under the “Events Calendar” in the Investors section of ObsEva’s website at


The randomized, double-blind, placebo-controlled, parallel-group trial was designed to assess the efficacy, safety and pharmacokinetics of ebopiprant. In this study, 113 women (83 singletons, 30 twins) with spontaneous preterm labor (gestational age between 24 and 34 weeks) were randomized and treated with atosiban (ex-U.S. standard of care) plus ebopiprant or atosiban plus placebo for 7 days. There were 83 (73%) women with singleton pregnancies and 30 (27%) with twin pregnancies. One hundred and forty-one neonates were born. Ebopiprant or placebo was administered orally, with 1000 mg as a starting dose (within 24 hours after starting the atosiban infusion), then 500 mg twice a day for 7 days. Women were assessed up to 14 days (unless delivery occurred sooner) and then again at delivery and up to 28 days after delivery. Follow-up of infants at 6, 12 and 24 months after birth. The efficacy endpoints assessed were delivery within 48 hours of starting treatment, delivery within 7 days of starting treatment, delivery before 37 weeks of gestation, and time to delivery. Safety assessments included maternal, fetal and neonatal safety. Infants are being followed-up at 6, 12 and 24 months. For additional information on this trial (NCT03369262), please visit

About Ebopiprant and PGF

ObsEva is developing ebopiprant, a potential first-in-class, once daily, oral and selective prostaglandin F receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin. Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015. ObsEva retains worldwide, exclusive, commercial rights.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit

About RCOG

The RCOG is a medical charity that champions the provision of high-quality women’s healthcare in the UK and beyond. It is dedicated to encouraging the study and advancing the science and practice of obstetrics and gynaecology. It does this through postgraduate medical education and training and the publication of clinical guidelines and reports on aspects of the specialty and service provision. If you would like to request a Press pass to the congress please email

Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva’s product candidates, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office contact
Shauna Dillon
+41 22 552 1550

Investor Contact:
Joyce Allaire
+1 (617)-435-6602


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Painter 2022: Must-Have Upgrade for Professional Artists Delivers a Faster, More Powerful Digital Painting Experience22.6.2021 15:01:00 CEST | Press release

Offering unprecedented performance, a streamlined workflow, and improved layer productivity, Painter 2022 makes it easier than ever for artists to create exceptional work OTTAWA, June 22, 2021 (GLOBE NEWSWIRE) -- Painter 2022 responds to users’ top requests and delivers a must-have upgrade by expanding creative possibilities. Designed for Windows 10 and macOS, this powerful and creative digital painting software adds enhancements that focus on accelerating workflows, boosting brush performance, and improving layer productivity to offer a game-changing digital art studio for today’s professional and aspiring artists. “We know the critical role Painter plays in professional artists’ workflows and are honored to be part of the creative process of bringing some of pop culture's most iconic movies, characters and games to life,” said Chris Pierce, Director of Product for Photo and Digital Arts at Corel. “With this version we focused on our customers’ top requests and whether it’s improvemen

IMCD N.V. shareholders adopt all resolutions at AGM22.6.2021 13:55:00 CEST | Press release

ROTTERDAM, The Netherlands (22 June 2021) – IMCD N.V. (hereafter “IMCD” or the “Company”) announces that all resolutions proposed to the shareholders at the Company’s Annual General Meeting (“AGM”) held today were adopted. This includes the adoption of the financial statements for the year 2020 and approval of the dividend proposal of EUR 1.02 per share in cash. The dividend calendar is as follows: Thursday 24 June 2021 - Ex-dividend date Friday 25 June 2021 - Record date Monday 28 June 2021 - Payment date Further resolutions included the reappointment of Deloitte Accountants B.V. as external auditor for the year 2021. The 2020 Remuneration Report received a positive advisory vote with over 94% of voted casted in favor of the report. Details of the Annual General Meeting, including the voting results, are available at IMCD’s corporate website. Attached, please find the press release in pdf format. Attachment PR_IMCD 2021 AGM resolutions

About making of a mandatory share buy-back offer22.6.2021 13:25:00 CEST | Press release

Joint stock company “Olainfarm”, hereinafter referred to as - “the Company”, hereby informs that on the 22nd of June, 2021 Joint stock company “AS “AB CITY””, registration number 40203174414, according to the clause 1 of the article 73 of the Financial Instrument Market Law, informed the Board of the Company about making of a mandatory share buy-back offer. The Board of the joint stock company “Olainfarm” will prepare conclusion and announce its opinion about the offer within terms set by the Financial Instrument Market Law after an advertisement regarding making of a share buy-back offer is published. Additional information: Jānis Dubrovskis Investor Relations Advisor of JSC Olainfarm Phone: +371 29178878 Email:

Verisk’s AIR Updates Its Terrorism Model to More Comprehensively Model Damage from Conventional Bomb Blast Attacks22.6.2021 12:11:00 CEST | Press release

BOSTON, June 22, 2021 (GLOBE NEWSWIRE) -- Catastrophe modeling firm AIR Worldwide announced that it has updated its Terrorism Model for the United States to more comprehensively model the extent of damage from conventional bomb blast attacks. Starting with the size and location of the bomb, the model propagates the appropriate blast intensity within a built environment from the exterior to the interior of buildings to yield damage and loss estimates, including property damage and workers’ compensation, and personal injury. AIR Worldwide is a Verisk (Nasdaq:VRSK) business. “When terrorists use conventional weapons—the effects of which tend to be highly localized—they are likely to be targeting specific buildings or facilities,” said Tao Lai, vice president, research, AIR Worldwide. “The amount of damage that occurs at or near the site of an attack depends on a wide variety of factors. In addition to the type of weapon used, the surrounding buildings, building dimensions and blast intens


RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2021-06-22Loan2311 Coupon1.00 %ISIN-codeSE0010948240Maturity2023-11-13 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln2,020Volume bought, SEK mln500Number of bids6Number of accepted bids2Average yield0.034 %Lowest accepted yield0.033 %Highest yield0.034 %% accepted at lowest yield 56.82 Auction date2021-06-22 Loan2505 Coupon1.00 %ISIN-codeSE0011414010Maturity2025-05-12 Tendered volume, SEK mln1,000 +/- 500 Volume offered, SEK mln3,000Volume bought, SEK mln1,000Number of bids8Number of accepted bids1Average yield0.219 %Lowest accepted yield0.219 %Highest yield0.219 %% accepted at lowest yield 100.00 Auction date2021-06-22 Loan2805 Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln750 +/- 350 Volume offered, SEK mln1,000Volume bought, SEK mln750Number of bids3Number of accepted bids1Average yield0.623 %Lowest accepted yield0.623 %Highest yield0.623 %% accepted at lowest yield 100.00


Bid date, 2021-06-22Auction date2021-06-22Settlement date2021-06-23Maturity Date2021-06-30Nominal amount490 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume490 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term979 billion SEKExpected excess liquidity at full allotment489 billion SEK Stockholm, 2021-06-22